Pharma Marketletter - Novartis’ Diovan as effective as Norvasc in hypertensive patients with high CVD risk.
Results have been published in The Lancet from the eagerly-awaited VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial, which compared Novartis’ angiotensin II receptor blocker Diovan (valsartan) with Pfizer’s calcium antagonist Norvasc (amlodipine) in hypertensive patients at high cardiovascular risk.
Most Popular
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Public Speakers
Business Plan Sample
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
The prospective, double-blind, randomized, active-controlled study involved 15,245 high blood pressure patients at risk for cardiovascular complications because of co-existing diseases or risk factors such as diabetes, history of stroke and coronary heart disease. The trial was primarily designed to evaluate, …
Want to read the whole article? You can purchase it here. It’s quick and easy.
